Lupin strengthens on launching generic Niaspan Tablets in US

21 Mar 2014 Evaluate

Lupin is currently trading at Rs. 947.50, up by 7.50 points or 0.80% from its previous closing of Rs. 940.00 on the BSE.

The scrip opened at Rs. 941.10 and has touched a high and low of Rs. 952.65 and Rs. 941.00 respectively. So far 23071 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1003.00 on 03-Mar-2014 and a 52 week low of Rs. 606.20 on 09-Apr-2013.

Last one week high and low of the scrip stood at Rs. 958.00 and Rs. 928.50 respectively. The current market cap of the company is Rs. 42398.72 crore.

The promoters holding in the company stood at 46.76% while Institutions and Non-Institutions held 43.22% and 10.02% respectively.

Lupin’s US subsidiary - Lupin Pharmaceuticals Inc. has launched its Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the United States Food and Drug Administration (USFDA).

Lupin’s Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths are the AB-rated generic equivalent of AbbVie Inc.’s Niaspan Tablets 500 mg, 750 mg, 1000 mg and used with diet to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. As per IMS MAT Dec, 2013, Niaspan Tablets had annual US sales of approximately $1 billion.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

 

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×